ASSOCIATION GENETHON

Their core work

Genethon is a French research centre dedicated to developing gene therapies for rare genetic diseases, from vector design through to clinical trials. They specialize in adeno-associated virus (AAV) vectors for in vivo gene therapy, targeting conditions like Crigler-Najjar syndrome, muscular dystrophies, glycogen storage diseases, and inherited immunodeficiencies. Their work spans the full translational pipeline — from CRISPR-based gene correction at the bench to Phase II clinical trials in patients. Genethon also contributes to broader efforts accelerating advanced therapy medicinal products (ATMPs) for rare diseases.

What they specialise in

How they've shifted over time

In the early period (2015–2017), Genethon's H2020 work was broader — spanning anti-neuroinflammatory approaches (low-dose IL-2 in MIROCALS), immunodeficiency (SCIDNET), and early-stage proof-of-concept genetic correction studies. From 2018 onward, their focus sharpened decisively toward AAV-mediated in vivo gene therapy and clinical translation, with projects like CureCN and UshTher moving into actual patient trials. The recent addition of ARDAT (2020) signals a move toward platform-level acceleration of advanced therapies across multiple rare diseases, suggesting Genethon is positioning itself as a clinical-stage gene therapy hub rather than a purely preclinical lab.

Genethon is moving from preclinical gene correction research toward running and supporting clinical-stage AAV gene therapies for rare diseases, making them an increasingly relevant partner for translational and regulatory work.

How they like to work

Genethon operates as both a project leader and a specialist partner, coordinating 4 out of 10 projects — typically the smaller, focused Marie Curie fellowships and proof-of-concept studies — while joining larger clinical consortia (CureCN, UshTher, ARDAT) as a key technical contributor. With 95 unique partners across 19 countries, they maintain a wide European network rather than relying on a closed circle of repeat collaborators. This dual profile — capable of leading focused studies and contributing deep gene therapy expertise to large consortia — makes them a flexible partner to approach.

Genethon has collaborated with 95 distinct partners across 19 countries, indicating a well-connected European network. Their partnerships span academic medical centres, biotech companies, and clinical sites, consistent with the multi-site nature of gene therapy clinical trials.

What sets them apart

Genethon occupies a rare position as a non-profit research centre with end-to-end gene therapy capability — from vector manufacturing and preclinical development through to clinical trials — specifically for rare diseases that are often too small-market for pharma to pursue. Their combination of AAV vector expertise, CRISPR gene editing work, and clinical trial infrastructure in a single organization makes them a one-stop partner for anyone working on genetic therapies. For consortium builders, they bring both the science and the translational infrastructure that most academic labs lack.

Highlights from their portfolio

• CureCN
  Largest project by far (EUR 4M), coordinated by Genethon, running a clinical trial of AAV gene therapy for Crigler-Najjar syndrome — their flagship translational effort.
• UshTher
  Pioneering dual-AAV vector approach for retinitis pigmentosa in Usher syndrome patients, pushing the technical limits of AAV payload capacity.
• ARDAT
  Most recent project (2020–2026), part of a broad platform to accelerate advanced therapies for rare diseases, signaling Genethon's shift toward ecosystem-level impact.